Protein kinase inhibitors: breakthrough medicines and the next generation

被引：8
作者：
Sawyer, Tomi K. [1 ]
Wu, Joe C. [2 ]
Sawyer, Jonathon R. [3 ]
English, Jessie M. [4 ]
机构：
[1] Aileron Therapeut, Cambridge, MA 02139 USA
[2] GlaxoSmithKline PLC, Cambridge, MA 02139 USA
[3] Providence Coll, Providence, RI 02908 USA
[4] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2013年 / 22卷 / 06期
关键词：
kinase inhibitor; protein kinase; proteins; small-molecule; IMATINIB; THERAPY;
D O I：
10.1517/13543784.2013.804509
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In this issue of Expert Opinion on Investigational Drugs, several protein kinases families and pathways underlying cancer and other diseases are reviewed and several small molecule inhibitors that are in clinical trials are further described. Highlights of these reviews and drug evaluations are summarized in this editorial.
引用
收藏
页码：675 / 678
页数：4
相关论文
共 14 条
  • [1] System-based drug discovery within the human kinome
    Bamborough, Paul
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2012, 7 (11) : 1053 - 1070
  • [2] Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
    Bose, Prithviraj
    Simmons, Gary L.
    Grant, Steven
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 723 - 738
  • [3] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
    Capdeville, R
    Buchdunger, E
    Zimmermann, J
    Matter, A
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) : 493 - 502
  • [4] Kinase Drug Discovery - What's Next in the Field?
    Cohen, Philip
    Alessi, Dario R.
    [J]. ACS CHEMICAL BIOLOGY, 2013, 8 (01) : 96 - 104
  • [5] Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
    Derenzini, Enrico
    Younes, Anas
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 775 - 785
  • [6] Axitinib for the treatment of advanced non-small-cell lung cancer
    King, Judy W.
    Lee, Siow-Ming
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 765 - 773
  • [7] Therapeutic potential of serum and glucocorticoid inducible kinase inhibition
    Lang, Florian
    Voelkl, Jakob
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 701 - 714
  • [8] Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer
    Nelson, Valerie
    Altman, Jessica K.
    Platanias, Leonidas C.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 715 - 722
  • [9] AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
    O'Hare, Thomas
    Shakespeare, William C.
    Zhu, Xiaotian
    Eide, Christopher A.
    Rivera, Victor M.
    Wang, Frank
    Adrian, Lauren T.
    Zhou, Tianjun
    Huang, Wei-Sheng
    Xu, Qihong
    Metcalf, Chester A., III
    Tyner, Jeffrey W.
    Loriaux, Marc M.
    Corbin, Amie S.
    Wardwell, Scott
    Ning, Yaoyu
    Keats, Jeffrey A.
    Wang, Yihan
    Sundaramoorthi, Raji
    Thomas, Mathew
    Zhou, Dong
    Snodgrass, Joseph
    Commodore, Lois
    Sawyer, Tomi K.
    Dalgarno, David C.
    Deininger, Michael W. N.
    Druker, Brian J.
    Clackson, Tim
    [J]. CANCER CELL, 2009, 16 (05) : 401 - 412
  • [10] Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes
    Prada, Patricia O.
    Saad, Mario J. A.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 751 - 763
12